Title:
良性腫瘍の予防または治療薬
Document Type and Number:
Japanese Patent JP7393752
Kind Code:
B2
Abstract:
The present disclosure provides a composition for preventing or treating a benign tumor. Provided is a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a specific embodiment, the present disclosure provides a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a preferred embodiment, the composition for preventing or treating a benign tumor (e.g. familial adenomatous polyposis) according to the present disclosure comprises a killer type WT1 peptide and/or a helper type WT1 peptide. In a further preferred embodiment, the WT1 peptide is WT1126 killer peptide and/or WT135 helper peptide. In another aspect, provided are a method of inducing WT1 peptide-specific CTLs, a method of inducing WT1-specific helper T cells, and a method of inducing dendritic cells presenting a WT1 peptide.
Inventors:
Haruo Sugiyama
Application Number:
JP2020551127A
Publication Date:
December 07, 2023
Filing Date:
October 04, 2019
Export Citation:
Assignee:
Cancer Immunology Institute Co., Ltd.
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd.
International Classes:
A61K38/08; A61K35/15; A61K35/17; A61K38/10; A61K39/00; A61K39/39; A61K48/00; A61P35/00; A61P37/04; A61P43/00; C12N5/0783; C12N5/0784
Domestic Patent References:
| JP2017523784A |
Foreign References:
| WO2016093326A1 | ||||
| WO2018181648A1 | ||||
| WO2014157692A1 |
Other References:
NAPEKOSKI K.M. et al.,Microvenular hemangioma: a clinicopathologic review of 13 cases.,Journal of Cutaneous Pathology,2014年,Vol.41, No.11,pages 816 to 822,doi:10.1111/cup.12386
SHIRAKATA T. et al.,WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.,Anticancer Research,2012年,Vol.32, No.3,pages 1081 to 1085,ISSN:0250-7005
大内知之ほか,多形腺腫由来癌carcinoma ex pleomorphic adenomaと転移性多形腺腫metastasizing pleomorphic adenoma,北海道医療大学歯学雑誌,2007年,Vol.26, No.2,pages 85 to 86,https://hsuh.repo.nii.ac.jp/?action=pages_view_main&active_action=repository_view_main_item_detail&item_id=10080&item_no=1&page_id=13&block_id=17
LANGMAN G. et al.,WT1 expression in salivary gland pleomorphic adenomas: a reliable marker of the neoplastic myoepithe,Modern Pathology,2011年,Vol.24, No.2,pages 168 to 174,doi:10.1038/modpathol.2010.190
WEBER G. et al.,WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implication,Leukemia,2009年,Vol.23, No.9,pages 1634 to 1642,doi:10.1038/leu.2009.70
KOIDO S. et al.,Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific M,Clinical Cancer Research,2014年,Vol.20, No.16,pages 4228 to 4239,doi:10.1158/1078-0432.CCR-14-0314
AMINI NIK S. et al.,Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors.,International Journal of Cancer,2005年,Vol.114, No.2,pages 202 to 208,doi:10.1002/ijc.20717
野村昌哉ほか,下行結腸カルチノイド根治術後7年目に異時性発生した上行結腸カルチノイドの1例,日本消化器外科学会雑誌,2004年,Vol.37, No.2,pages 217 to 222,https://doi.org/10.5833/jjgs.37.217
BAUTZ D.J. et al.,Prophylactic vaccination targeting ERBB3 decreases polyp burden in a mouse model of human colorectal,Oncoimmunology,2016年,Vol.6, No.1, Article No. e1255395,pages 1 to 6,doi:10.1080/2162402X.2016.1255395
ASLAN A. et al.,Investigation of Insulin-Like Growth Factor-1 (IGF-1), P53, and Wilms' Tumor 1 (WT1) Expression Leve,Medical Science Monitor,2019年07月25日,Vol.25,pages 5510 to 5517,doi:10.12659/MSM.915335
SHIRAKATA T. et al.,WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.,Anticancer Research,2012年,Vol.32, No.3,pages 1081 to 1085,ISSN:0250-7005
大内知之ほか,多形腺腫由来癌carcinoma ex pleomorphic adenomaと転移性多形腺腫metastasizing pleomorphic adenoma,北海道医療大学歯学雑誌,2007年,Vol.26, No.2,pages 85 to 86,https://hsuh.repo.nii.ac.jp/?action=pages_view_main&active_action=repository_view_main_item_detail&item_id=10080&item_no=1&page_id=13&block_id=17
LANGMAN G. et al.,WT1 expression in salivary gland pleomorphic adenomas: a reliable marker of the neoplastic myoepithe,Modern Pathology,2011年,Vol.24, No.2,pages 168 to 174,doi:10.1038/modpathol.2010.190
WEBER G. et al.,WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implication,Leukemia,2009年,Vol.23, No.9,pages 1634 to 1642,doi:10.1038/leu.2009.70
KOIDO S. et al.,Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific M,Clinical Cancer Research,2014年,Vol.20, No.16,pages 4228 to 4239,doi:10.1158/1078-0432.CCR-14-0314
AMINI NIK S. et al.,Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors.,International Journal of Cancer,2005年,Vol.114, No.2,pages 202 to 208,doi:10.1002/ijc.20717
野村昌哉ほか,下行結腸カルチノイド根治術後7年目に異時性発生した上行結腸カルチノイドの1例,日本消化器外科学会雑誌,2004年,Vol.37, No.2,pages 217 to 222,https://doi.org/10.5833/jjgs.37.217
BAUTZ D.J. et al.,Prophylactic vaccination targeting ERBB3 decreases polyp burden in a mouse model of human colorectal,Oncoimmunology,2016年,Vol.6, No.1, Article No. e1255395,pages 1 to 6,doi:10.1080/2162402X.2016.1255395
ASLAN A. et al.,Investigation of Insulin-Like Growth Factor-1 (IGF-1), P53, and Wilms' Tumor 1 (WT1) Expression Leve,Medical Science Monitor,2019年07月25日,Vol.25,pages 5510 to 5517,doi:10.12659/MSM.915335
Attorney, Agent or Firm:
Norito Yamao
Michiko Matsutani
Yoko Sakurai
Michiko Matsutani
Yoko Sakurai
Previous Patent: Rare earth mud collection method and environmental load reduction method
Next Patent: concentration measuring device
Next Patent: concentration measuring device